Fundraising Fox

Richard Heyman

Investor

Venture Partner at ARCH Venture Partners

Encinitas, California

Writes $50K – $150M checks Β· typically $25M

Experience

  1. Pelage PharmaceuticalsBoard Membercurrent2025 β€” present
  2. Architect TherapeuticsChairman of the BOD and Co-Foundercurrent2023 β€” present
  3. ORIC PharmaceuticalsChairman of the BODcurrent2014 β€” presentSouth San Francisco
  4. Enliven TherapeuticsBOD Member/Chairmancurrent2020 β€” present
  5. Vividion Therapeutics, Inc.BOD member/Former Chairmancurrent2018 β€” present
  6. PMV Pharmaceuticals, Inc.Chairman of the Boardcurrent2020 β€” present
  7. ARCH Venture PartnersVenture Partnercurrent2020 β€” present
  8. Nextech InvestScience Partnercurrent2022 β€” present
  9. Salk Institute for Biological StudiesMember Board of Trusteescurrent2015 β€” presentLa Jolla, CA
  10. CureboundBoard Member and Scientific Advisory Board Membercurrent2021 β€” present
  11. Life Science Cares San DiegoBoard of Managerscurrent2020 β€” present
  12. RayzeBioChairman of the Board2022 β€” 2023
  13. Metacrine Inc.Executive Chairman2015 β€” 2022San Diego
  14. Amunix PharmaceuticalsChairperson of the Board2019 β€” 2021
  15. Yumanity TherapeuticsBOD Member2016 β€” 2021Cambridge, Ma
  16. Gritstone OncologyBOD Member2015 β€” 2021Emeryville, CA
  17. Seragon PharmaceuticalsPresident and CEO2013 β€” 2015
  18. Aragon PharmaceuticalsPresident and CEO2009 β€” 2013
  19. Kalypsys, Inc.Chief Scientific Officer2006 β€” 2008
  20. Exelixis, Inc.Sr. Vice President2004 β€” 2006

Education

  1. University of MinnesotaPhD, Pharmacology1980 β€” 1986

Skills & more

Drug Discovery99Biotechnology79Lifesciences25Molecular Biology28Biochemistry24Pharmacology51Clinical Development38Drug Development82Cell Culture18Oncology30Pharmaceutical Industry51Cell Biology21
+3 moreIn VitroAssay DevelopmentIn Vivo

From Richard's professional profile.

Same school

Shared employers

Deals Β· 3

Enliven Therapeutics, Inc.Board seat

via ARCH Venture Partners Β· filed Apr 2024 Β· $90M raise

Vividion TherapeuticsBoard seat

via ARCH Venture Partners Β· filed May 2019 Β· $82M raise

MetacrineBoard seat

via ARCH Venture Partners Β· filed Nov 2016 Β· $37.8M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at ARCH Venture Partners